Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis
SM Galbraith, MA Lodge, NJ Taylor… - NMR in Biomedicine …, 2002 - Wiley Online Library
The purpose of this study was to determine the reproducibility of dynamic contrast‐enhanced
(DCE)‐MRI and compare quantitative kinetic parameters with semi‐quantitative methods, …
(DCE)‐MRI and compare quantitative kinetic parameters with semi‐quantitative methods, …
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results
GJS Rustin, SM Galbraith, H Anderson… - Journal of clinical …, 2003 - ascopubs.org
Purpose: A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel
tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. …
tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors. …
Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma
…, J Siegel, SD Chasalow, J Weber, S Galbraith… - Cancer immunity, 2010 - AACR
Blockade of cytotoxic T-lymphocyte antigen-4 (CTLA-4) by ipilimumab leads to immune-mediated
tumor regression and immune-related adverse events (irAEs), including diarrhea and …
tumor regression and immune-related adverse events (irAEs), including diarrhea and …
[PDF][PDF] Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging
SM Galbraith, RJ Maxwell, MA Lodge… - Journal of clinical …, 2003 - pfeifer.phas.ubc.ca
Purpose: Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic
contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to …
contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to …
ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature
PD Davis, GJ Dougherty, DC Blakey, SM Galbraith… - Cancer research, 2002 - AACR
Physiological differences between tumor and normal vasculature provide a target for drug
discovery. In particular, the immature nature of tumor vasculature may render it intrinsically …
discovery. In particular, the immature nature of tumor vasculature may render it intrinsically …
Metabolism and disposition of dasatinib after oral administration to humans
…, A Allentoff, FYF Lee, B McCann, S Galbraith… - Drug metabolism and …, 2008 - ASPET
SPRYCEL (dasatinib, BMS-354825; Bristol-Myers Squibb, Princeton, NJ), a multiple kinase
inhibitor, is currently approved to treat chronic myelogenous leukemia and Philadelphia …
inhibitor, is currently approved to treat chronic myelogenous leukemia and Philadelphia …
[PDF][PDF] Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung …
…, A Bezjak, JS Humphrey, M Voi, S Galbraith… - Journal of clinical …, 2005 - academia.edu
Purpose To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase
inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non–small-…
inhibitor (MMPI), added to systemic chemotherapy improved survival in advanced non–small-…
Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma
…, DY Wu, SM Parker, S Galbraith… - Journal of …, 2012 - journals.lww.com
Ipilimumab, a fully human monoclonal antibody, which blocks cytotoxic T-lymphocyte antigen-4,
has demonstrated an improvement in overall survival in 2 phase III trials of patients with …
has demonstrated an improvement in overall survival in 2 phase III trials of patients with …
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies
…, AA Lammertsma, SM Galbraith - Journal of Nuclear …, 2009 - Soc Nuclear Med
18 F-FDG PET is often used to monitor tumor response in multicenter oncology clinical trials.
This study assessed the repeatability of several semiquantitative standardized uptake …
This study assessed the repeatability of several semiquantitative standardized uptake …
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
SM Galbraith, DJ Chaplin, F Lee, MR Stratford… - Anticancer …, 2001 - europepmc.org
Background Combretastatin A4 Phosphate (CA4P) is a tubulin binding agent which causes
rapid tumour vascular shutdown. It has anti-proliferative and apoptotic effects on dividing …
rapid tumour vascular shutdown. It has anti-proliferative and apoptotic effects on dividing …